Using gold compounds to treat aggressive breast cancer
Gold-derived therapeutic compounds for disease application
This study is exploring new gold-based treatments for triple negative breast cancer, which is a tough type of breast cancer to treat, and aims to find options that can shrink tumors and stop them from spreading while being gentle on healthy cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10886713 on NIH RePORTER |
What this research studies
This research focuses on developing gold-derived therapeutic compounds to target triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer with limited treatment options. The approach involves creating a library of gold compounds that have shown high potency against cancer cells while sparing normal cells. By studying how these compounds affect mitochondrial functions in cancer cells, the research aims to identify effective treatments that can significantly reduce tumor growth and prevent metastasis. The compounds have already demonstrated promising results in preclinical models, indicating their potential for future clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who do not have cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for patients suffering from triple negative breast cancer.
How similar studies have performed: Other research has shown success with gold-based compounds in cancer treatment, suggesting a promising avenue for further exploration.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Awuah, Samuel Gorman — University of Kentucky
- Study coordinator: Awuah, Samuel Gorman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.